|
Johann Wolfgang Goethe University Hospital Becomes Second Training Center in Europe to Treat Patients with Delcath Hepatic CHEMOSAT® Delivery System NEW YORK, Feb. 27, 2012 /PRNewswire/ -- Delcath Systems, Inc., (NASDAQ: DCTH) announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT® Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011. Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications. Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, "We believe this technology has significant potential to help control cancers in the liver. We're pleased to be the first cancer center to begin offering this important treatment option to patients in Germany, and are eager to further explore its role in the treatment of multiple tumor types including breast cancer." "Delcath's partnership with J.W. Goethe reinforces the potential of CHEMOSAT," said Eamonn P. Hobbs, president and CEO of Delcath. "We recently treated our first patients in Milan and are eager to continue our expansion across Europe. Opening another CHEMOSAT treatment center and treating patients in the continent's largest market is another step forward in the commercialization of this technology." About the Johann Wolfgang Goethe University Hospital Founded in 1914, J.W. Goethe University Hospital is considered to be one of the leading university hospitals in Germany. Twenty-five research institutes working in close cooperation with the Medical Department bear witness to the hospital's strong academic approach. This makes sure that patients coming to the University Hospital for treatment enjoy the benefits resulting from timely implementation of research findings. Every year, around 47,200 and 220,000 patients respectively receive in- and outpatient treatment. The University Hospital possesses special interdisciplinary competence in the fields of neurological science, oncology and cardiovascular medicine. SOURCE Delcath Systems, Inc. |
|
| aus der Diskussion: | Mit Delcath Systems "seperat" die Chemo einsetzen! |
| Autor (Datum des Eintrages): | McNay (29.02.12 20:06:50) |
| Beitrag: | 15 von 68 (ID:42828906) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |